1. INTRODUCTION {#sec1}
===============

HBV infection is an epidemic in Asia, Africa, Southern Europe and Latin America, and HBV consists of at least eight genotypes (A-H) \[[@r1]\]. Several factors have been known to be related to higher HCC risk among HBV carriers: demographic (male gender, older age, ethnicity), genetic (family history of HCC), viral (high viral load, viral genotype, duration of infection, co-infection with HCV, HIV or HDV), and environmental (exposure to aflatoxin, alcohol abuse or cigarette smoking) \[[@r2], [@r3]\]. Generally, HBV is the main causative agent in the high incidence HCC areas, while HCV is the major etiological factor related to HCC in low incidence HCC areas \[[@r2], [@r4]-[@r6]\]. In addition, HDV chronic infection has been found to be associated with a worsening of HBV infection. Usually, it increased the risk of liver decompensation and Hepatocellular Carcinoma (HCC) occurrence \[[@r7]\]. Furthermore, HBV DNA and HBeAg were detected less frequently in anti-HD-positive than in anti-HD-negative subjects among patients with severe liver disease \[[@r8]\]. These findings indicated that HBV infection was closely related to HDV infection, although the mechanism kept unclear.

Among HBV genotypes, HBV/B and HBV/C are more restricted to east/south-east Asia \[[@r9]\]. HBV infection of these two types has been known as a leading cause for chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC) in China \[[@r10]\]. The integration events of HBV/B and HBV/C are also frequent to be detected in the cancer tissues of HCC patients.

Massive Parallel Sequencing (MPS) technology has provided an efficient mean to detect HBV integration through whole genome. Jiang *et al.* investigated the effect of HBV integration by whole genome sequencing. They found that HBV integration could trigger the copy number variation of genome and induce the abnormal expression \[[@r11]\]. Sung *et al.* had surveyed the hotspot genes of HBV integration through the whole genome and determined that there was a significant relationship between HBV integration and survival time \[[@r12]\]. Furthermore, the researcher found that the viral-human chimeric transcript may trigger the Wnt signaling pathways and had close relation with the development and progression of liver cancer \[[@r13]\]. Based on the above studies, it suggested that HBV integration is an important event in the process of tumorigenesis. HBV integration can not only cause genetic damage and chromosomal instability but also cause disorder to the host gene expression \[[@r14]\]. In addition, expression of viral proteins such as X protein and S antigen may further induce the tumorigenesis \[[@r13]\]. Indeed, the first descriptions of HBV integration events were based on primary HCC tissues and HCC-derived cell lines, prompting suggestions that HBV integration events might be causative in tumorigenesis \[[@r15], [@r16]\]. Hitherto, the reported mechanisms include (1) HBV integration mediated insertional mutagenesis of HCC-associated genes; (2) induction of chromosomal instability by HBV integration; (3) the expression of HBV genes from the HBV integration. However, the mechanism of HBV-induced HCC carcinogenesis still remains unclear so far \[[@r17]\].

However, the samples in these studies were collected *via* invasive procedures. In order to facilitate the clinical utilization, HBV integration events in plasma were urgently needed to be surveyed. The characteristic of HBV integration in the plasma might promote the clinical utilization potential of HBV integration.

A high throughput virus integration detection (HIVID) approach was adopted to investigate the HBV integration sites \[[@r18]\]. Overall, there were 15 samples with HBV integration among 20 plasma samples and 87 breakpoints were found in the 15 plasma samples. Furthermore, we determine the characteristic of HBV integration sites in the plasma samples. HBV integration was prone to the region of INTRON. Pathway analysis indicated that the HBV integration events were enriched in the pathway of cancer. Altogether, our results provided evidence for the HBV integration in these plasma samples and explored the characteristic of HBV integration in the plasma, which might be useful for HCC prognosis and diagnosis.

2. MATERIALS AND METHODS {#sec2}
========================

2.1. Sample Collection and Plasma DNA Extraction {#sec2.1}
------------------------------------------------

We obtained the plasma and tumor tissue samples from the Affiliated Hospital of Jining Medical University, Jining, China, and patients had been diagnosed with HCC. All patients signed the written informed consent form, and the study had been approved by the Ethics Review Committee in the Jining Medical University. Plasma was stored at 80°C and DNA was extracted from a 0.5-ml plasma aliquot with DNA Blood Midi Kit (Qiagen, Germany) according to the manufacturer's instructions and stored at -20°C before further analysis. The inclusion criteria for this study included: (i) HBV-positive HCCs (HBV-B type) (ii) obtained from consenting patients and (iii) all patients were HCV-negative and HIV-negative (iv) negative for autoimmune hepatitis and metabolic and/or genetic disorders, such as Wilson's disease, hemochromatosis.

2.2. HBV Fragments Enrichment and Sequencing {#sec2.2}
--------------------------------------------

The construction of sequencing library strictly followed the standard instructions provided by Illumina. The cell free DNA purified, and their ends were blunted, "A" tailed, ligated to adaptors and then PCR. The DNA libraries were quantified using Bioanalyser 2100 (Agilent Technologies, Santa Clara, CA, USA). The hybridization procedures were carried out following MyGenostics's GenCapTM Target Enrichment Protocol (GenCapTM Enrichment, MyGenostics, USA). The DNA libraries were hybridized with HBV probes at 65°C for 24 hours and subsequently subjected to washes to remove unbound. The eluted fragments were amplified by 12 PCR cycles in order to generate the sequencing library. Each library was further quantified and proceeded to 101 cycles of paired-end index sequencing in the Illumina HiSeq 2000 sequencer according to the manufacturer's official instruction.

2.3. Breakpoints Detection and Annotation of HBV Integration Sites {#sec2.3}
------------------------------------------------------------------

Deploying an algorithm established by our team previously \[[@r18]\], the low-quality reads, duplication reads and adaptor contaminations were removed. Subsequently, the filtered clean reads were mapped to both the human (NCBI build 37, HG19) and the HBV genomes. The chimeric reads that partially aligned to the human genome and partially aligned to the HBV genome were remained as the reads of our interest. The selected chimeric reads were then subjected to paired-end reads assembly, which helped to reconstruct fragment sequences, and additionally increased the efficacy to locate the precise position of the breakpoints. The PE-assembled reads were re-mapped to the human and the HBV genome using BWA \[[@r19]\]. The HBV integration breakpoints were annotated using ANNOVAR \[[@r20]\].

3. RESULTS {#sec3}
==========

3.1. The Distribution of Breakpoints in the Human Genome {#sec3.1}
--------------------------------------------------------

Plasma samples of 20 HCC patients were obtained in order to investigate the HBV integration sites (Table **[1](#T1){ref-type="table"}**). The DNA of plasma was processed according to our innovative HIVID approach \[[@r18]\]. Among the samples, 15 samples showed positive for HBV integration, altogether 87 integration sites were determined (Table **[2](#T2){ref-type="table"}**). Among all the integration sites, 46 of them were in the intron region, and 24 were in the intergenic region (Table **[3](#T3){ref-type="table"}**). Therefore, it seems that the breakpoints were more prone to be enriched in the intron region (Fig. **[1a](#F1){ref-type="fig"}**; Intron observed ratio=0.53; Intron random ratio=0.34; Chisquare Test *P*\<0.01).

3.2. The Distribution of Breakpoints in the HBV Genome {#sec3.2}
------------------------------------------------------

The distribution of breakpoints in the HBV genome was then analysed. It was also revealed that the breakpoints from plasma samples were enriched in the region of 1700-2000 bp of the HBV genome specifically (Fig. **[1b](#F1){ref-type="fig"}**).

3.3. The Pathway Analysis of Breakpoints {#sec3.3}
----------------------------------------

Using DAVID pathway enrichment software, the genes integrated by HBV were analysed \[[@r21], [@r22]\], and the results indicated that cancer pathway was particularly targeted (*P*\<0.01). These five genes *CTNNA2, EGFR, MITF, STK36* and *RALA* were located in the cancer pathway.

4. DISCUSSION {#sec4}
=============

HBV integration had previously been demonstrated having a close association with the tumorigenesis of HCC. In the studies led by Sung *et al.,* the authors had identified several genes preferentially integrated by HBV \[[@r12]\]. In this study, our team had analysed the HBV integration sites in 20 plasma samples of HCC patients. The results suggested that the genes in the cancer pathway were particularly targeted by HBV integration. In recent years, the use of plasma DNA sample in clinical diagnosis has become increasingly important \[[@r23]\], this is due to the presence of circulating DNA originated from the degenerating tumor cells \[[@r24]\]. According to the established data, one of the major sources of plasma or serum DNA may be from the apoptotic cells \[[@r25]\], though the entire mechanism of DNA being released into circulating blood still remains to be thoroughly investigated.

Generally, there was a significant portion of the cf-DNA from the tumor tissues. Many researchers have identified that common genetic alterations exist in both tumor tissue and paired plasma samples \[[@r26]\]. The level and characteristic of cf-DNA in human plasma have been affected by the dynamic balance between cellular DNA release and DNA degradation. Thus, stability of distinct cf-DNA forms \[[@r27], [@r28]\], activity of blood nucleases \[[@r29]\], adsorption of cf-DNA on blood cells \[[@r30], [@r31]\], as well as degradation of cf-DNA by phagocytes should also be considered as factors regulating the characteristic and level of cf-DNA in cancer patients \[[@r32]\].

Moreover, it is curious to find a number of breakpoints located in the intergenic regions. In recent years, an increasing trend of research interests had drawn to resolve the usefulness of breakpoints located in the intergenic region. For instances, MYC activation was driven by an upstream integration of HPV-18 genome \[[@r33]\]; β-catenin transactivity could be modulated by HBV integration in Long Interspersed Nuclear Element (LINE) \[[@r13]\]. Thus the importance and significance of HBV integration sites in the intergenic region remain elusive.

The distribution of breakpoints in the HBV genome was also investigated. It was revealed that the breakpoints were particularly enriched in the region of HBV X and core genes, which is in line with the previous findings by others and also our group.

CONCLUSION
==========

Our study had adopted an effective method to seek HBV integration sites in the plasma samples. The results provided evidence for HBV integration in the plasma samples, which could be potentially useful for future HCC prognosis and diagnosis.
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###### 

Demographic and clinicopathologic characteristics of 20 HCC patients.

  **Variables**                                 **Mean ± SD / n (%)**
  --------------------------------------------- -----------------------
  **Age, years**                                49.5±7.2
  **Sex**                                       
  Female                                        5 (25%)
  Male                                          15 (75%)
  **Diagnosis**                                 
  Primary HCC                                   20 (100%)
  **HCC Differentiation (Edmondson-Steiner)**   
  II                                            2 (10%)
  III                                           18 (90%)
  **Tumor diameter, cm**                        6.2±4.3
  **Microvascular invasion**                    
  Absence                                       15 (75%)
  Presence                                      5 (25%)
  **ALB, g/L**                                  43.9±5.1
  **TBIL, µmol/L**                              16.1±5.7
  **PT, seconds**                               11.9±1.1
  **AFP, µg/L**                                 579.8±564.8
  **HBV type**                                  
  HBV_B                                         20 (100%)
  **HBV DNA levels, IU/mL**                     417825.9±856030.9
  **HBeAg**                                     
  Positive                                      6 (30%)
  Negative                                      14 (70%)
  **Anti-HBe status**                           
  Positive                                      17 (85%)
  Negative                                      3 (15%)
  **HBsAg status**                              
  Positive                                      20 (100%)
  **Anti-HBs status**                           
  Negative                                      20 (100%)

###### 

Data production of samples. Breakpoint number in human genome and coverage of HBV genome were shown.

  **Library**   **Total Bases**   **Q20**       **HBV Type**   **HBV Coverage**   **Breakpoint Number**
  ------------- ----------------- ------------- -------------- ------------------ -----------------------
  B001          5.42G             88.42;79.57   B              99%                3
  B002          5.01G             86.90;78.08   B              98%                4
  B0074         5.22G             85.49;80.51   B              97%                7
  B0068         5.31G             86.97;79.88   B              99%                2
  B0064         5.40G             87.38;81.57   B              99%                3
  B0061         5.81G             86.08;78.67   B              100%               9
  B0049         5.12G             85.49;80.55   B              99%                5
  B0037         5.16G             88.97;81.86   B              96%                6
  B0032         5.20G             86.55;81.97   B              97%                5
  B0075         5.25G             87.89;79.72   B              98%                7
  B007          5.86G             83.50;81.52   B              99%                5
  B0034         5.27G             87.87;80.78   B              97%                8
  B0021         5.68G             86.78;82.47   B              99%                5
  B0012         5.09G             88.77;79.88   B              98%                6
  B0010         5.50G             84.52;81.63   B              99%                12
  B0016         5.91G             85.87;79.25   B              96%                0
  B0011         5.53G             89.67;81.98   B              98%                0
  B008          5.57G             86.98;78.66   B              99%                0
  B009          5.61G             85.59;80.79   B              99%                0
  B005          5.55G             86.49;79.74   B              99%                0

###### 

The breakpoints of plasma samples. The breakpoints detected in the plasma samples.

  **Sample**   **Chr**   **Position**   **Support**   **Element**      **Gene**
  ------------ --------- -------------- ------------- ---------------- ---------------------
  B0074        chr4      8977829        4             intergenic       LOC650293/USP17L10
  B0074        chr8      103211319      2             downstream       RRM2B
  B0074        chr8      30611415       2             intronic         UBXN8
  B0074        chr8      103119207      2             intronic         NCALD
  B0074        chr4      125111322      2             intergenic       LINC01091/ANKRD50
  B0074        chr4      65178643       2             intronic         TECRL
  B0074        chr20     47656089       2             promoter         CSE1L
  B0068        chr4      118968708      2             intronic         NDST3
  B0068        chr17     21903348       2             promoter         FLJ36000
  B0064        chr11     65986345       8             intronic         PACS1
  B0064        chr1      249121201      7             promoter         SH3BP5L
  B0064        chr15     34708490       4             intergenic       GOLGA8A
  **Sample**   **Chr**   **Position**   **Support**   **Element**      **Gene**
  B0061        chr18     22570340       7             intergenic       RP11-449D8.1/ZNF521
  B0061        chr6      169471301      4             intergenic       SMOC2/THBS2
  B0061        chr3      110721179      4             intergenic       LINC01205/PVRL3-AS1
  B0061        chr7      74141512       3             ncRNA_intronic   LOC101926943
  B0061        chr21     39816650       3             intronic         ERG
  B0061        chr4      86519608       2             intronic         ARHGAP24
  B0061        chr2      45757229       2             intronic         SRBD1
  B0061        chr1      225407594      2             intronic         DNAH14
  B0061        chr1      10649629       2             intronic         PEX14
  B0049        chr7      55273463       4             UTR3             EGFR
  B0049        chr4      92355373       3             intronic         CCSER1
  B0049        chr6      31003961       2             downstream       MUC22
  B0049        chr4      31901689       2             intergenic       PCDH7
  B0049        chr3      49089016       2             intronic         QRICH1
  B0037        chrX      112015468      2             downstream       AMOT
  B0037        chr2      28331047       2             intronic         BRE
  B0037        chr17     33939459       2             intronic         AP2B1
  B0037        chr14     100715229      2             intronic         YY1
  B0037        chr10     57261124       2             intergenic       PCDH15/MTRNR2L5
  B0037        chr1      38451027       2             intronic         SF3A3
  B0032        chr17     21906061       4             ncRNA_intronic   FLJ36000
  B0032        chr17     21906355       3             ncRNA_intronic   FLJ36000
  B0032        chr11     191802         3             promoter         LOC653486
  B0032        chr4      49649534       2             intergenic       CWH43
  B0032        chr17     21903348       2             promoter         FLJ36000
  B0075        chr8      30611415       3             intronic         UBXN8
  B0075        chr5      7349039        3             intergenic       LOC442132/ADCY2
  B0075        chr3      73158614       3             intergenic       PPP4R2/PDZRN3
  B0075        chr8      124890891      2             intronic         FER1L6
  B0075        chr4      100009507      2             intronic         ADH5
  B0075        chr18     22570340       2             intergenic       RP11-449D8.1/ZNF521
  B0075        chr12     27136775       2             intronic         TM7SF3
  B007         chr10     89954886       6             intergenic       PTEN/RNLS
  B007         chr10     89954930       4             intergenic       PTEN/RNLS
  B007         chr11     47814540       3             intronic         NUP160
  B007         chr7      72974855       2             promoter         BCL7B
  B007         chr18     42356727       2             intronic         SETBP1
  **Sample**   **Chr**   **Position**   **Support**   **Element**      **Gene**
  B0034        chr12     30265504       5             intergenic       TMTC1/IPO8
  B0034        chr2      119052347      4             intergenic       INSIG2/LOC101927709
  B0034        chr15     67917548       4             intronic         MAP2K5
  B0034        chr12     33057564       3             promoter         PKP2
  B0034        chr9      98598152       2             ncRNA_intronic   LINC00476
  B0034        chr6      32546766       2             UTR3             HLA-DRB1
  B0034        chr6      32546685       2             UTR3             HLA-DRB1
  B0034        chr4      42527080       2             intronic         ATP8A1
  B0021        chr7      39673979       9             intronic         RALA
  B0021        chr7      129485990      2             intronic         UBE2H
  B0021        chr7      40234460       2             intronic         SUGCT
  B0021        chr17     43211456       2             intronic         ACBD4
  B0021        chr17     43211378       2             intronic         ACBD4
  B0012        chr5      58123101       3             intronic         RAB3C
  B0012        chr2      80380053       3             intronic         CTNNA2
  B0012        chr17     39084514       3             exonic           KRT23
  B0012        chr1      173786892      3             intronic         CENPL
  B0012        chrX      61684765       2             intergenic       SPIN4
  B0012        chr7      158778486      2             intergenic       WDR60/LINC00689
  B0010        chr4      184204577      3             intronic         WWC2
  B0010        chr3      69838919       3             intronic         MITF
  B0010        chr17     7267199        3             downstream       TMEM95
  B0010        chr16     1723993        3             exonic           CRAMP1L
  B0010        chr14     69887597       3             intronic         SLC39A9
  B0010        chr10     56134248       3             intronic         PCDH15
  B0010        chr1      111605674      3             intergenic       LRIF1/DRAM2
  B0010        chr9      20278555       2             intergenic       SLC24A2/MLLT3
  B0010        chr9      68429933       2             ncRNA_intronic   LOC642236
  B0010        chr9      6881037        2             intronic         KDM4C
  B0010        chr8      88368708       2             intronic         CNBD1
  B0010        chr8      124052577      2             intronic         DERL1
  B002         chr5      52674905       2             intergenic       LOC257396/FST
  B002         chr3      42691176       2             promoter         ZBTB47
  B002         chr12     38638139       4             intergenic       ALG10B
  B002         chr2      28693259       2             intergenic       FOSL2/PLB1
  B001         chr2      219543519      2             intronic         STK36
  B001         chr2      219543501      4             intronic         STK36
  B001         chr18     11550976       11            intergenic       PIEZO2/SLC35G4

[^1]: *These authors contributed equally to this work*.
